Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
War Data Platform enables standardized data for agentic AI applications Advana modernization includes financial management and application migration Explore AI,…
Noblis MSD has won a five-year, single-award IDIQ contract to provide end-to-end engineering services for the Network Integration Engineering Facility…
The acquisition expands Empower AI’s capabilities in AI, cloud, data management and DevSecOps Highlight Technologies adds digital modernization and AI-driven…
